Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
Surgopaedia
Search
Search
Appearance
Create account
Log in
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Editing
Phaeochromocytoma
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== '''Epidemiology''' == * Affects about 0.2% of patients with HTN * Peak incidence between 40-50yo * Familial cases can manifest earlier and more often multifocal * '10%' axiom is not really true in modern times ** Bilateral ** Malignant ** Extra-adrenal ** Familial == Risk factors == * MEN 2 (50% penetrant) * VHL (10-20% penetrant) * NFT 1 (1-5% penetrant) * Germline mutations in succinate dehydrogenase (lifetime penetrance >75%) ** See separate topic under 'oncology' == Pathophysiology == * Malignancy ** 2.5-40% are malignant, depending on underlying phenotype ** No histopathologic criteria exist for determining malignancy ** Malignancy is defined by development of metastases (defined as distant implants in locations where neuroectodermal tissues are not normally found) ** Most common metastatic sites are axial skeleton, lymph nodes, liver, lung and kidney * Paragangliomas ** Tend to secrete noradrenaline rather than adrenaline == '''Presentation''' == * Classic triad - headache, diaphoresis, palpitations ** Almost all patients will have at least one * HTN (90%) - can be episodic or sustained == '''Diagnosis''' == * Biochemical ** Need to confirm elevated levels of catecholamines and their metabolites in body fluids. The exact profiles vary; tumours have different characteristics depending on their expression of synthetic and degradative enzymes. ** Testing rationale *** Plasma metanephrines/normetanephrines: sensitivity 99%, specificity 85% **** Drawn in supine position, and after an overnight fast, avoiding caffeine and nicotine *** 24-hour urine catecholamines and metabolites: specificity 99% **** Considered positive when total metanephrines or any single catecholamine fraction is elevated above its cut-off value. This maintains high specificity and yields a sensitivity of about 88%. *** Given that phaeochromocytoma is a rare diagnosis within a large pool of hypertensive patients, false-positives are a real problem, and specificity is crucial. It has been estimated that false-positives outnumber true positives by up to 30:1 when plasma metanephrines are used as screening. ** Drugs and conditions that can cause elevated metanephrines: *** Sympathomimetics *** Phenoxybenzamine *** Paracetamol *** Psychotropic drugs including TCAs *** Major physical or psychological stressors ** Approach *** Start with serum metanephrines *** If positive, test urine *** Clonidine suppression testing (give 0.3mg oral clonidine) can be used but is uncommonly needed * Anatomical localisation/staging ** CT or MRI can be used - CT is often more useful, but MRI is slightly more sensitive *** CT - characteristic - heterogenous with higher attenuation. All phaeos have HU > 10. *** MRI - bright on T2 ** Scintigraphy with (131)I or (123)I-labeled metaiodobenzylguanidine (MIBG) can be performed when multifocal or malignant disease is suspected *** Highly specific, but sensitivity only 77-90% ** PET (F-DOPA) which somehow uses DOTATATE is developing as superior to MIBG, but apparently isn't widely available yet * Check for genetic syndromes * Histopathological ** PASS score - composite of capsular or vascular invasion, mitotic rate, necrosis ** GAPP - phaeos and paragangliomas - combines histopathological and clinical criteria - probably the more favoured score now == '''Differential diagnosis''' == * Hyperthyroidism * Hypoglycaemia * CAD * CCF * CVA * Drug effects * Panic disorder == '''Phaeochromocytoma in pregnancy''' == * Rare, but potentially fatal (29% mortality if diagnosed in labour or post-partum) * Adrenalectomy in second trimester * Postpone surgery until after delivery if diagnosed in third trimester == '''Treatment approach''' == * Surgical resection of primary and metastatic lesions, which can also have palliative responses in the absence of a cure, due to reducing the systemic impact of catecholamine release * Malignant tumours are minimally responsive to radiotherapy and chemotherapy ** I-MIBG radionuclide therapy has a 22% complete or partial response rate, with significant toxicities and questionable long-term benefit * Chronic medical management can be achieved with alpha1-adrenergic blockers === '''Surgery''' === * Minimise tumour manipulation, avoid rupture * Tumours tend to be highly vascular and adherent to adjacent structures * Mostly can be removed laparoscopically, but prefer open with signs of local invasion or tumours >6cm === '''Peri-op care''' === * Pre-op care ** Start with phenoxybenzamine 10mg BD (alpha-adrenergic blockade) as soon as the biochemical diagnosis is made *** This drug is a non-specific, non-competitive (irreversible), long-acting (half-life 24 hours), alpha-adrenergic antagonist *** Side effects postural hypotension and nasal congestion (which can actually serve as a useful indicator of adequate blockade) *** Other options would be prazosin or doxazosin ** Titrate upwards every 2-3 days to a maximum of 40mg TDS to achieve normalisation of HR and BP ** Calcium channel blockers can be added if this is inadequate BP control after titration ** Beta blockers can be added with persistent tachycardia ** Pre-op conditioning should last at least two weeks to allow adequate reversal of alpha-adrenergic receptor down-regulation. This restores sensitivity to vasopressor agents, which can then be used to treat the patient post-operatively. ** Pre-operative volume repletion is generally not indicated - once blockade is achieved, patients can restore volume by drinking to thirst ** Needs pre-op staging * Intra-op HTN ** Caused by stimulation of catecholamine release by induction agents, along with direct manipulation of the tumour ** Intra-operative alpha-adrenergic blockade followed by aggressive volume repletion and alpha-adrenergic agonists in the immediate post-op period ** Art-line is required ** Pause for 10 mins if BP getting very high ** Ligate vein before arteries * Post-op HTN ** Can be profound - state of hypovolaemia created by the presence of excess circulating catecholamines. Sudden withdrawal leads to peripheral arteriolar vasodilation and a dramatic increase in venous capacitance, which together may precipitate CV collapse. ** Aggressively resuscitate if hypotension or oliguria occurs ** Vasopressors may be required == '''Prognosis''' == * Surgery is curative in >90% of cases == '''Indications for genetic testing''' == * Age <45yo * Multiple tumours * Head and neck paraganglioma [[Category:Endocrine]]
Summary:
Please note that all contributions to Surgopaedia may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Surgopaedia:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Phaeochromocytoma
Add topic